NCT01126294

Brief Summary

Patients undergoing lumbar laminectomy surgery will receive either 5 or 10 mg melatonin or placebo once the evening before surgery and again 90 minutes before surgery. Pain and anxiety will be assessed over the 24 hour period following surgery.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
84

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2010

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 17, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 19, 2010

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2011

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2011

Completed
Last Updated

May 19, 2010

Status Verified

April 1, 2010

Enrollment Period

1.2 years

First QC Date

May 17, 2010

Last Update Submit

May 18, 2010

Conditions

Keywords

lumbar laminectomy, melatonin, perioperative, pain, anxiety, analgesia, VAS score

Outcome Measures

Primary Outcomes (2)

  • Pain

    Pain will be assessed over a 24 hour period following surgery using a visual analogue scale

    24 hours

  • Anxiety

    Anxiety will be assessed over a 24 hour following surgery using visual analogue scale

    24 hours

Study Arms (3)

Melatonin 5 mg

EXPERIMENTAL

Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.

Dietary Supplement: 5 mg melatonin

Melatonin 10 mg

EXPERIMENTAL

Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.

Dietary Supplement: 10 mg melatonin

Placebo

PLACEBO COMPARATOR

Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.

Dietary Supplement: Placebo

Interventions

5 mg melatoninDIETARY_SUPPLEMENT

Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.

Melatonin 5 mg
10 mg melatoninDIETARY_SUPPLEMENT

Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.

Melatonin 10 mg
PlaceboDIETARY_SUPPLEMENT

Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.

Placebo

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age 18 to 65 years old
  • ASA status 1-3
  • having lumbar laminectomy 2 to 3 levels with or without fusion

You may not qualify if:

  • receiving emergent procedure
  • surgery for neoplastic spine lesion
  • allergy to melatonin or its non-medicinal ingredients
  • allergy or contraindication
  • BMI over 35 or or less than 20 kg/m2
  • pregnancy or breastfeeding
  • failure to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto Western Hospital

Toronto, Ontario, M5T 2S8, Canada

RECRUITING

Related Publications (1)

  • Madsen BK, Zetner D, Moller AM, Rosenberg J. Melatonin for preoperative and postoperative anxiety in adults. Cochrane Database Syst Rev. 2020 Dec 8;12(12):CD009861. doi: 10.1002/14651858.CD009861.pub3.

MeSH Terms

Conditions

PainAnxiety DisordersAgnosia

Interventions

Melatonin

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental DisordersPerceptual DisordersNeurobehavioral ManifestationsNervous System Diseases

Intervention Hierarchy (Ancestors)

TryptaminesIndolesHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsHormonesHormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

  • Philip Peng, MD

    University Health Network, Toronto

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Philip Peng, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

May 17, 2010

First Posted

May 19, 2010

Study Start

April 1, 2010

Primary Completion

July 1, 2011

Study Completion

September 1, 2011

Last Updated

May 19, 2010

Record last verified: 2010-04

Locations